Chemotherapy: Open Access

Chemotherapy: Open Access
Open Access

ISSN: 2167-7700

+32 28087017

Michelle Fanale

Michelle Fanale

Michelle Fanale
Department of Lymphoma/Myeloma
University of Texas, USA

Biography

Dr. Michelle A Fanale is an Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, TX USA. She received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark, NJ, USA. She completed her internal medicine residency at the Mayo Clinic in Rochester, MN, USA, followed by a fellowship in medical oncology and haematology at the MD Anderson Cancer Center.  Dr. Fanale focuses in caring for and clinical research for patients with Hodgkin lymphoma, T-cell lymphoma, Burkitt‘s and double-hit lymphomas, and HIV-associated lymphomas. In the field of Hodgkin lymphoma she has be a principal investigator (PI) for multiple clinical research trials, including for a series of trials with brentuximab vedotin (SGN-35) which has recently been FDA approved in August 2011 for treatment of relapsed and refractory classical Hodgkin and anaplastic large cell lymphoma. In addition she has recently completed a phase I trial and then a phase II trial evaluating bortezomib (B) plus ifosfamide, cyclophosphamide, etoposide (ICE) versus ICE for relapsed/refractory classical Hodgkin lymphoma. She also has an ongoing clinical classical Hodgkin lymphoma trial through Southwest Oncology Group (SWOG) evaluating the use of mid-treatment PET/CT scan results for stratification of front-line treatment intensity.

Research Interest

Furthermore, she is also interested in improving treatment strategies for patients with the rare diagnosis of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and has conducted a retrospective study evaluating outcomes with R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) and has a under review with SWOG a phase II randomized protocol for patients with advanced stage NLPHL evaluating R-CHOP versus R-ABVD (Rituximab, Doxorubicin, Vinblastine, Dacarbazine). Her research has been presented at national and international meetings and her studies have been published in prestigious peer reviewed journals.

Top